MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z
  • ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD

    N. Giladi, Y. Caraco, T. Gurevich, R. Djaldetti, L. Adar, T. Rachmilewitz Minei, S. Oren (Tel Aviv, Israel)

  • ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data

    L. Adar, C. Durlach, O. Yacoby Zeevi, D. Fishelovitch, S. Oren (Rehovot, Israel)

  • Network for parallel gamma synchronizations during upper limb movement

    G. Tamas, A. Anwar, G. Deuschl, J. Raethjen, S. Groppa, M. Muthuraman (Budapest, Hungary)

  • Neural correlates of minor hallucinations in Parkinson’s disease: A multimodal imaging study

    H. Bejr-kasem, J. Pagonabarraga, S. Martinez-Horta, F. Sampedro, J. Marin-Lahoz, J. Perez-Perez, A. Horta-Barba, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

  • Neural correlates of movement sequence kinematics in substantia nigra dopaminergic cells

    M. Mendonça, J. Alves Silva, L. Hernandez, J. Obeso, R. Costa (Lisboa, Portugal)

  • Neural Correlates Underlying Reward Processing and Decision-Making in Impulse Control Disorder in Parkinson´s Disease

    I. Navalpotro-Gomez, P. Paz-Alonso, P. Boddy, M. Delgado-Alvarado, H. Jimenez-Urbieta, A. Quiroga-Varela, B. Gago, M. Carreiras, M.C. Rodriguez-Oroz (San Sebastian, Spain)

  • Neuroactive steroids reverse the dopaminergic neurotransmission defectiveness in chronic hepatic (HE) encephalopathy: a possible involvement in HE related parkinsonism

    O. El Hiba, A. EL Khiat, H. Gamrani (EL Jadida, Morocco)

  • Neuroanatomical correlates of depressive symptoms in newly diagnosed Parkinson’s disease patients

    S.J. Kim (Busan, Republic of Korea)

  • Neurodegenerative biomarker abnormality frequency in idiopathic REM sleep behavior disorder

    A. Boeve, S. McCord, P. Timm, D. Sandness, N. Commers, E. Duwell, G. Tabatabai, S. McCarter, M. Junna, M. Lipford, M. Tippmann-Peikert, B. Boeve, M. Silber, E. St. Louis (Rochester, MN, USA)

  • Neuroferritinopathy pedigree in 2 families from India

    J. Kaur, G. Singh, B. Paul (Ludhiana, India)

  • Neurofilament light chain levels in cerebrospinal fluid do not discriminate between patients with prion disease and mimics

    B. Roeben, E. Stransky, K. Brockmann, R. Schüle, W. Maetzler, T. Gasser, G. Machetanz (Tübingen, Germany)

  • Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson’s disease and multiple system atrophy

    K.J. Kim, J.-M. Kim (Seongnam-Si, Republic of Korea)

  • Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms

    D. Claassen, C. Adler, C. Gibbons, L.A. Hewitt (Nashville, TN, USA)

  • Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review

    J. Fernandez Bonfante, G. Pagano, M. Politis (London, United Kingdom)

  • Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration

    M. Duffy, T. Collier, K. Luk, M. Tansey, K. Paumier, D. Fischer, N. Polinski, C. Kemp, C. Sortwell (Grand Rapids, MI, USA)

  • Neurological examination of motor Functional Neurological Disorders: an evidence-based review towards the development of consensus guidelines from the Committee on Research of the ANPA

    S. Aybek, D. Perez, W.C. LaFrance, C. Stephen, R. Shura, S. Glass, S. Ducharme, V. Voon (Bern, Switzerland)

  • Neurological worsening in patients undergoing treatment for Wilson disease: Frequency, causes and outcomes.

    A. Aggarwal, M. Bhatt (Mumbai, India)

  • Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease

    L. Correia Guedes, S. Reimão, P. Paulino, R. Nunes, R. Bouça, D. Abreu, N. Gonçalves, T. Soares, M. Fabbri, C. Godinho, P. Lobo, D. Neutel, M. Quadri, M. Coelho, M.M. Rosa, J. Campos, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

  • Neuroprotection and Alleviation of Parkinsonian Phenotypes by Ayurvedic Herbs

    S. Singh, J. Prakash, S. Yadav (Varanasi, India)

  • Neuroprotection of indole-derivative compound NC001-8 in Parkinson disease cell model by regulatory of NRF2 pathway

    P.-C. Wei (Tao-Yuan, Taiwan)

  • Neuroprotective effect of α-Mangostin in restoration mitochondrial function in MPTP-Induced Parkinson’s disease in mice

    A. Prakash, A.B. Majeed, K. Ramasamy, M. Hasan (Baltimore, MD, USA)

  • Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

  • Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease

    R. Banerjee, D. Nthenge-Ngumbau, R. Singh, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

  • Neuroprotective propensity of PTUPB, a dual inhibitor of sEH and COX-2 against rotenone induced neurotoxicity in cell line and Drosophila model of Parkinson disease

    N. Lakkappa, P. Thaggikuppe Krishnamurthy, P.D. Mirazkar, N. Lakkappa, P. Krishnamurthy, P.M.D., M.M. Srinivas Bharath, B. Hammock, S.H. Hwang (Udhagamandalam, India)

  • Neuropsychiatric and Cognitive Predictors of Early Diagnosis of Progressive Supranuclear Palsy

    C. Pellicano, F. Assogna, N. Cellupica, M. Pierantozzi, A. Stefani, R. Cerroni, B. Mercuri, C. Caltagirone, F. Pontieri, G. Spalletta (Rome, Italy)

  • Neuropsychiatric symptoms after bilateral stimulation in Parkinson’s disease: subthalamic nucleus versus globus pallidus internus.

    F. Fonoff, E. Fonoff, R. Machado, R. Cury, M.G. dos Santos, E. Barbosa (São Paulo, Brazil)

  • Neuropsychological predictors of patient-reported cognitive outcomes following deep brain stimulation

    K. Mills, K. Donohue, A. Swaminathan, J.-M. Leoutsakos, J. Brandt (Baltimore, MD, USA)

  • Neuropsychological profile of corticobasal degeneration, progressive supranuclear palsy and frontotemporal dementia patients

    M.M. Carmona-Abellan, M. Riverol, M. Recio, B. Echeveste, L. Imaz, R. Luquin (Pamplona, Spain)

  • Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study

    N. Titova, N. Sotnikova, E. Katunina (Moscow, Russian Federation)

  • Neurotological Findings in Sporadic Ataxia

    B. Zeigelboim, H. Teive, K. Kronbauer, A. Scheidt, J. Faryniuk, T. Oliveira, A. Lacerda (Curitiba, Brazil)

  • New device HANABI (HANdai Amyloid Burst Inducer) is a rapid and sensitive detecting system of α synuclein fibril in CSF from Parkinson’s disease patients

    K. Ikenaka, K. Araki, M. So, S. Hashimoto, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

  • New method to evaluate new motor skill learning

    A.P. Quixadá, V. Sotero, J.-F. Daneault, G. Diaz, Â. Torres, J.P. Vieira, M. Fonseca, P. Bonato, N. Peña, J.G. Miranda (Salvador, Brazil)

  • New XK deletion associated with McLeod syndrome

    A. DoedeMaindreville, G. Jouret, E. Landais, P. Feucher, S. Bakchine, D. Gaillard, A.S. Lebre (Reims, France)

  • Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, M. Hebron, Y. Torres-Yaghi, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, A. Shekoyan, J. Ahn, C. Moussa (Washington, DC, USA)

  • Noladin ether attenuates MPTP -induced motor deficit by abrogating pro-inflammatory cytokines and striatal neurochemical alterations in rats

    R. Deshmukh, S. Singh (Moga, India)

  • Non motor symptoms in patients with Writer’s cramp

    R. Singh, P. Chatterjee, S. Choudhury, S. Anand, S. Shubham, S. Trivedi, H. Kumar (Kolkata, India)

  • Non-Invasive Assessment of Swallowing and Respiration Coordination in Early Parkinson’s Disease

    Y.R. Wu, C.-M. Wang, W.-Y. Shieh, Y.-H. Weng, Y.-H. Hsu (Taoyuan, Taiwan)

  • Non-motor features of p.A53T α-synuclein mutation carriers compared to sporadic Parkinson’s disease in a PPMI cohort .

    M. Stamelou, C. Koros, A. Simitsi, I. Beratis, X. Geronicola Trapali, D. Papadimitriou, N. Papagiannakis, A. Prentakis, D. Kontaxopoulou, S. Fragkiadaki, R. Antonelou, S. Papageorgiou, L. Stefanis (Athens, Greece)

  • Non-motor symptom burden is associated with thalamic atrophy in Parkinson’s disease

    F. Niccolini, H. Wilson, B. Giordano, K. Diamantopoulos, G. Pagano, K. Ray Chaudhuri, M. Politis (London, United Kingdom)

  • Non-motor symptoms and gender differences in multiple system atrophy

    S. Eschlboeck, T. Benke, S. Bösch, M. Delazer, A. Djamshidian-Tehrani, A. Fanciulli, R. Granata, B. Högl, C. Kaindlstorfer, G. Kiss, F. Krismer, K. Mair, M. Nocker, C. Raccagni, C. Scherfler, K. Seppi, A. Stefani, W. Poewe, G. Wenning (Innsbruck, Austria)

  • Non-motor symptoms in a cross section of PD patients with varying degrees of smell loss

    c. cox, A. Khattab, K. Amar (Bournemouth. Dorset, United Kingdom)

  • Non-motor symptoms in ACDY5-associated disease

    C. Amlang, M. Vidailhet, M. Amlang (Bronx, NY, USA)

  • Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients

    M. Qamar, A. Sauerbier, A. Rizos, K. Chaudhuri (London, United Kingdom)

  • Non-motor symptoms in Parkinsons’s disease patients treated with levodopa-carbidopa intestinal gel infusion- the follow up study

    A. Križnar, N. Zupančič Križnar, M. Kramberger, J. Bon, R. Rajnar, L. Ocepek, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

  • Non-motor symptoms in patients with Parkinson’s disease, essential tremor and both diseases – a group comparison

    I. Wurster, A. Abaza, K. Brockmann, M. Rüdiger-Albers, S. Lerche, D. Berg (Tübingen, Germany)

  • Non-motor symptoms in the first neurology consultation in Cali – Colombia

    J. Valderrama-Chaparro, J. Sanchez-Morante, Y. Ariza-Araujo, A. Enriquez-Marulanda, B. Munoz, J. Orozco (cali, Colombia)

  • Non-Progressive Coreoatethosis Secondary to Infantile Necrotizing Encephalopathy Mimicking Leigh Disease.

    G. Fabiani, H. Teive (Curitiba, Brazil)

  • Noninvasive cerebellar stimulation for adults with cervical dystonia

    A. McCambridge (Sydney, Australia)

  • NonMotor and Motor symptoms in Idiopathic Parkinson´s Disease and Secondary parkinsonism The “Parkinsons Well-Being MapTM” – a useful instrument in Clinical praxis.

    Ö. Skogar, M. Nilsson, S. Morberg (Jönköping SWEDEN, Sweden)

  • Nonmotor disorders in Parkinsonism: Experience in Kyrgyz Republic

    C. Shambetova (Bishkek, Kyrgyzstan)

  • Nonpharmacological therapies for sleep disturbances in Parkinson’s disease patients: A Systematic review

    J. Lee, Y. Kim (Seoul, Republic of Korea)

  • Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?

    J.E. Lee, J.-S. Kim, Y.-S. Oh, D.-W. Ryu, I.-U. Song, K.-S. Lee (Seoul, Republic of Korea)

  • Novel Programming Strategy to Overcome Loss of Efficacy in Essential Tremor

    S. Farris, M. Giroux (Englewood, CO, USA)

  • Novel TUBB4A variants in idiopathic dystonia

    S. Camargos, C. Dos Santos, F. Silva Junior, E. Barbosa, S.M. Azevedo Silva, V. Borges, J.C. Limongi, M.S. Rocha, H. Ferraz, F. Cardoso, P. Carvalho Aguiar (Belo Horizonte, Brazil)

  • NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders

    E. Dellapina, V. Chaigneau, F. Durif, J.-C. Corvol, O. Rascol, F. NS-PARK/FCRIN network (Toulouse, France)

  • NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy

    B. Balint, G. Charlesworth, M. Stamelou, L. Carr, N. Wood, K. Bhatia (London, United Kingdom)

  • Number and characteristics of people who requested the Portuguese Version of the European Physiotherapy Guideline for Parkinson’s Disease: a one-year follow-up

    L. Almeida, T. Capato, J. Domingos (Salvador, Brazil)

  • Nutritional status and changes in body weight in patients with multiple system atrophy

    T. Shimohata, T. Sato, M. Nishizawa (Niigata, Japan)

Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley